Treatment Options for Pneumonia in Patients with Penicillin Allergy

Outpatient Treatment Options

The American College of Physicians recommends respiratory fluoroquinolones (moxifloxacin, gemifloxacin, or levofloxacin) as the preferred first-line treatment option for patients with pneumonia and penicillin allergy, with a strength of evidence rated as high 1
Macrolides (azithromycin, clarithromycin, or erythromycin) are alternative options for penicillin-allergic patients, particularly when treating atypical pathogens, with a moderate strength of evidence 2
Doxycycline can be considered as an alternative option, particularly for patients who cannot tolerate fluoroquinolones or macrolides, with a low strength of evidence 3, 1

The Infectious Diseases Society of America recommends respiratory fluoroquinolone monotherapy (moxifloxacin, levofloxacin) as the preferred treatment for penicillin-allergic patients, with a high strength of evidence 3, 1
For severe pneumonia requiring ICU admission in penicillin-allergic patients, a respiratory fluoroquinolone plus aztreonam is recommended, with a moderate strength of evidence 3

For confirmed or suspected MRSA pneumonia, adding vancomycin or linezolid to the regimen is recommended, with a high strength of evidence 3
For influenza-associated pneumonia, adding oseltamivir to the antibiotic regimen is recommended, with a moderate strength of evidence 3, 1
For aspiration pneumonia in penicillin-allergic patients, clindamycin can be considered, with a low strength of evidence 1

For patients with non-severe, non-type I hypersensitivity reactions to penicillin, certain cephalosporins may be considered under medical supervision, with a moderate strength of evidence 4, 5
For patients with true type I (immediate) hypersensitivity reactions to penicillin, avoiding all beta-lactams and using fluoroquinolones or macrolides is recommended, with a high strength of evidence 4, 5

Considering local resistance patterns when selecting therapy, particularly for S. pneumoniae, is recommended, with a moderate strength of evidence 2

For penicillin-allergic patients requiring ICU admission, the Infectious Diseases Society of America recommends a regimen of respiratory fluoroquinolone (levofloxacin or moxifloxacin) PLUS aztreonam, as aztreonam substitutes for beta-lactam coverage without cross-reactivity risk in true penicillin allergy 6
When MRSA coverage is suspected or confirmed, adding vancomycin or linezolid to the base regimen is critical, as MRSA pneumonia carries significant mortality risk, according to the Clinical Infectious Diseases guidelines 6
For patients with pseudomonas risk factors, using an antipseudomonal fluoroquinolone (levofloxacin 750 mg or ciprofloxacin) plus aztreonam plus aminoglycoside is recommended, as stated in the Clinical Infectious Diseases journal 6

The minimum treatment duration is 5 days with clinical stability criteria met, and patient must be afebrile for 48-72 hours and have ≤1 sign of clinical instability before discontinuation, as per the Clinical Infectious Diseases guidelines 6
The Infectious Diseases Society of America recommends switching from IV to oral therapy when hemodynamically stable, clinically improving, able to take oral medications, and have normal GI function, and discharge as soon as clinically stable 6

The American Thoracic Society and the Infectious Diseases Society of America recommend that the first dose of antibiotics should be given in the emergency department for hospitalized patients to reduce mortality, as stated in the Clinical Infectious Diseases journal 6

The American Thoracic Society recommends doxycycline 100 mg orally twice daily as an alternative option for penicillin-allergic patients with community-acquired pneumonia, considering 200 mg as the first dose for rapid serum levels, with a strength of evidence supported by high-quality studies 7

The American College of Chest Physicians and other medical societies support the use of doxycycline as an alternative to fluoroquinolones for the treatment of community-acquired pneumonia in penicillin-allergic patients, with a strength of evidence based on clinical success rates exceeding 90% 7

The Infectious Diseases Society of America recommends adding vancomycin 15 mg/kg IV every 8-12 hours (target trough 15-20 mg/mL) OR linezolid 600 mg IV every 12 hours if MRSA is suspected or confirmed in patients with pneumonia, particularly those with risk factors such as post-influenza pneumonia, cavitary infiltrates on imaging, prior MRSA infection/colonization, or recent hospitalization with IV antibiotics 8
For patients with Pseudomonas risk factors, such as structural lung disease, bronchiectasis, severe COPD with frequent steroid/antibiotic use, or prior P. aeruginosa isolation, the Infectious Diseases Society of America recommends using antipseudomonal fluoroquinolone (levofloxacin 750 mg OR ciprofloxacin 400 mg IV every 8 hours) PLUS aztreonam 2 g IV every 8 hours PLUS aminoglycoside (gentamicin or tobramycin 5-7 mg/kg IV daily) 8

The American Thoracic Society recommends using respiratory fluoroquinolone (levofloxacin 750 mg IV daily OR moxifloxacin 400 mg IV daily) PLUS aztreonam 2 g IV every 8 hours for severe CAP requiring ICU admission in penicillin-allergic patients, as this combination provides dual coverage against pneumococcal and gram-negative pathogens required for severe disease 8